We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EoE

News List

FDA Grants Dupixent Breakthrough Therapy Designation for Eosinophilic Esophagitis americanpharmaceuticalreview
September 18, 2020
Regeneron Pharmaceuticals and Sanofi announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent® (dupilumab) for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE).
Dupixent Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints americanpharmaceuticalreview
June 01, 2020
Regeneron Pharmaceuticals and Sanofi announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE).
Fasenra Granted Orphan Drug Designation americanpharmaceuticalreview
September 03, 2019
AstraZeneca announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE).